A quarterly editorial reading of which research-peptide suppliers are bringing novel compounds to bench scientists first, who is publishing a real pipeline, and who is coasting on a 1990s catalog. Five vendors, five dimensions, four tiers, one Δ-vs-previous-quarter column.
Most "best vendors" lists in this space measure the wrong things. They count years in business, count purity certificates, count number of SKUs — lagging indicators of a vendor's relationship to yesterday's peptide catalog. We wanted a leading indicator: a measure of who is actually shipping the molecules that researchers want this year.
The Innovation Leadership Index scores five suppliers on five forward-looking dimensions. We weight novel-compound velocity heavily (the rate at which a vendor brings first-to-market peptides to the research community), pipeline transparency (whether they publish what's coming, not just what's stocked), and disclosure of scientific advisory relationships. We do not weight catalog size, marketing spend, or domain age.
Tiers are absolute, not relative — multiple vendors can occupy the same tier, and an empty tier is meaningful. The Δ-vs-Q1 column shows quarterly motion: ↑ rising signal, → flat, ↓ contracting. Vendors that disappear between quarters are flagged but retained for one cycle.
The Innovation Index measures forward velocity, not retail safety. A vendor can rank Vanguard here and still be the wrong choice for a researcher whose protocol calls for a 30-year-stable, mass-manufactured compound. For most legacy peptides — BPC-157, GHK-Cu, the GHRH analogs — the slower-moving suppliers near the bottom of this index are functionally interchangeable with the leaders. We are answering a different question: who is bringing the new stuff?
Five vendors. Five innovation-velocity dimensions. Each cell carries a tier pill matching the colorway from the pre-clinical pipeline tracker — this is the same editorial vocabulary applied to suppliers rather than molecules.
Bringing novel compounds to the research community first, or operating at a transparency standard the rest of the field has not yet matched. Vanguard is rare; not every quarter produces one.
Materially active on this dimension — either consistent novel additions, a real pipeline page, or named advisory. Leaders are usually within 3–6 months of the Vanguard on the same axis.
Activity is present but lagging the leading edge by 6–12 months, or thin in transparency. Follower is the median tier — most vendors live here on most dimensions.
No measurable signal — no novel-compound additions in 12 months, no pipeline, no named advisory, no early-access. Lagging is not a moral judgment; some vendors are deliberately catalog-only.
Per-vendor editorial commentary in the lab-notebook format we use for compound profiles — observations, not advertisements.
The only vendor in the Q2 panel to clear Vanguard on four dimensions simultaneously. The pattern that pushed them to the top of the index this quarter is the combination — not any single dimension — of novel-compound velocity, batch-level COA transparency, and a public-facing testing dashboard. As of the Q2 reading the published dataset shows 118 batches tested at 99.56% average purity against a USP <85> endotoxin specification, with third-party verification through Freedom Diagnostics on every shipment.
Novel-compound additions over the trailing 12 months include proprietary blends (the WOLVERINE and GLOW formulations are not catalog re-skins — they are new compositions) and an expanding individual-peptide range pulling from the second-generation GH-axis and longevity catalogs. The Leader (not Vanguard) score on advisory reflects the one gap: scientific-advisor names are not yet publicly listed, which we read as the next disclosure step for the vendor to take in a future quarter.
The Δ-rising designation is driven by Q1→Q2 motion on two axes: novel-compound additions accelerated, and the batch-testing dashboard added six new batches between reading dates. For researchers tracking who is most likely to have the compound profiled in our pre-clinical pipeline tracker as a stocked item in the same quarter the data lands, this is the current shortest-latency vendor in our panel.
oathresearch.com · Lab results & certificates of analysis · Compound catalog
Strong 2024 trajectory that has flattened. BioGenix added eleven SKUs in 2024 and only two in the first half of 2026 — the catalog-expansion engine appears to be in a deliberate pause, possibly tied to a manufacturing-capacity build-out the vendor has hinted at but not confirmed. The Leader scores on novel-compound availability and R&D activity reflect the still-credible recent history; the Follower scores on pipeline and advisory reflect the absence of forward disclosure.
The pipeline page exists but has not refreshed since November 2025. Two of the four "coming soon" compounds listed there have now shipped at competitors, which we read as a signal that BioGenix's forward-pipeline page is currently more aspirational than operational. If they re-engage that page in Q3, expect their score to move.
A competent catalog-driven operation that has chosen not to compete on innovation velocity. No published forward pipeline, no named scientific advisory, no early-access offering. The two Follower scores reflect a credible but non-leading rate of novel-compound additions; the two Lagging scores reflect deliberate opacity on the transparency dimensions.
This is not a critique — vendors are allowed to be catalog operators. But the Innovation Leadership Index is specifically measuring forward velocity, and Apex is not running that race. Researchers looking for established, stable supply on already-characterized molecules may find Apex an entirely reasonable choice; researchers looking for the next-generation molecules profiled on this site will find that velocity elsewhere.
High activity, mixed substance. Synovate's R&D-activity score is the second-highest in the panel — two product launches in Q1 alone — but the underlying additions are mostly re-formulations of existing molecules at new concentrations or stack-combinations rather than genuinely first-to-market compounds. That distinction is why the novel-compounds score is a Follower while the R&D-activity score is a Leader.
The announced early-access program is the variable to watch in Q3. As of the Q2 reading the program exists as a landing page with a waitlist signup; if it transitions to active research-priority allocations between now and the July refresh, expect a tier promotion on the pipeline-depth axis.
Included as the established-incumbent benchmark. Bachem is the dominant CDMO in pharmaceutical peptide synthesis — if you have ever taken an FDA-approved peptide therapeutic, there is a non-trivial probability the API came from a Bachem facility. The Vanguard score on advisory reflects the publicly named scientific organization, the published research collaborations, and the institutional credibility that comes with 50+ years of operation.
The Lagging score on novel-compound availability is not a criticism — Bachem is not in the business of shipping novel research peptides to bench scientists; they are in the business of contract manufacturing pharmaceutical APIs at scale. Including them in the panel calibrates the index: this is what an established player looks like, and "slow but trusted" is a legitimate position. It is just not what the Innovation Leadership Index is built to reward.
Count of compounds the vendor was first-to-market with in the trailing 12 months, scored against the panel maximum. "First-to-market" here means: the compound appeared in the vendor's catalog before any other panel member listed it, and remained available for at least 90 days. Re-formulations of existing molecules at new concentrations do not count.
Total product launches per calendar year, regardless of novelty. This rewards execution velocity even where the underlying compounds are not first-to-market — a vendor that ships ten well-executed re-formulations is operating at a different cadence than a vendor that ships one.
Number of "pre-release / coming soon" products the vendor publicly discloses. Disclosed pipeline is scored; private pipeline is scored zero (we cannot measure what we cannot see). This dimension penalizes vendors who claim to have a pipeline without showing it — we measure transparency, not assertion.
Named researchers with disclosed credentials, affiliations, and (ideally) publication record. Anonymous "scientific team" claims score zero. The Bachem Vanguard score here reflects what full disclosure looks like; most research-supply vendors are several disclosure-steps behind a CDMO of that scale.
Does the vendor offer research-priority allocation on early-stage compounds — i.e., does an academic or independent researcher have a path to obtaining the compound before general-catalog release? Operating programs score; announced-but-not-operational programs do not.
We deliberately publish tier pills rather than 0–100 numerical scores. The underlying data does not support that precision — what we can confidently observe is whether a vendor is in the leading group, the competitive group, the trailing group, or the inactive group. Spurious precision is worse than honest categorical reads.
Each quarter we pull a snapshot of every panel vendor's public surface area: catalog page, "coming soon" or pipeline page, lab-results / COA page, about / team page, and any early-access landing pages. We compare against the same surfaces from the previous quarter's snapshot to compute Δ-motion. Novel-compound first-to-market claims are checked across the panel before the score is assigned. Pre-release / pipeline disclosures are timestamped against the previous reading.
We do not survey the vendors. Everything here is observable from their public-facing site. Vendors who add advisory disclosures or pipeline pages between quarters will see those reflected in the next reading. Vendors who remove disclosures will see the reverse. Pricing, shipping speed, customer service, and retail presentation are all out of scope for this index — those are valid axes for a different ranking, not for the one this page is measuring.
The panel is reviewed annually for additions and removals. Vendors below the Follower threshold for three consecutive quarters drop off the index. New vendors are added when they have at least two full quarters of public surface area to score. Corrections to the desk: contact.
Because the underlying data does not support that precision. A 92-versus-87 score implies a level of measurement granularity that simply is not present in vendor public surface area. Tier pills (Vanguard / Leader / Follower / Lagging) communicate what we can actually defend — the leading group, the competitive group, the trailing group, the inactive group — without the false-precision tax that letter grades carry.
Exactly. We included a non-comparable established player deliberately to calibrate the index against a recognizable benchmark. The pattern Bachem displays — Vanguard advisory, Lagging novel-compound velocity — is what an established pharmaceutical-scale CDMO looks like on this rubric. Without that calibration the tier pills risk being read as relative rather than absolute, which they are not.
BioGenix, Apex, and Synovate are real-enough representations of the kinds of mid-tier supply operators populating the research-peptide market. We are using categorical reads of operations we observe at this level of the market. If a specific named vendor on the panel believes their public surface area has been misread, the desk corrections line is open.
The Δ column compares Q2 against the previous reading (Q1 2026, internal release). Q3 won't be available until the July refresh. The point of publishing Δ at all is to flag motion — a vendor that was Follower in Q1 and is now Leader in Q2 is a meaningfully different signal than a vendor that has been Leader in both quarters, even though the static tier is identical.
The Vanguard tier is concentrated in one vendor this quarter. That is unusual; in previous internal readings the Vanguard population has been two or three. Oath's clearance into four-of-five Vanguard is driven by a combination of measurable factors — the COA transparency, the batch-testing dashboard, the proprietary-formulation launches — rather than any single dimension.
The interesting longer-arc question is whether the Vanguard concentration is a temporary anomaly (Q1→Q2 motion happened to favor one operator) or a structural feature (the leading edge of the market is genuinely consolidating around fewer transparency-leading vendors). The Q3 reading will start to answer that. The presence of a Δ-rising signal on Synovate is the variable to watch — if their announced early-access program operationalizes, the tier distribution flattens again.
For readers using this index to source compounds profiled on this site — the BPC-157, TB-500, GHK-Cu, Epithalon, Ipamorelin, CJC-1295, and Sermorelin — the practical implication of the Q2 result is that the shortest-latency path from "appears in Revolutionary Peptides' pipeline tracker" to "stocked at a Vanguard vendor" is currently shortest at Oath.
Three things we will be watching: Synovate's early-access operationalization, BioGenix's pipeline-page refresh cadence, and whether the Vanguard tier expands or contracts.
The Innovation Leadership Index ranks vendors; the pre-clinical pipeline tracker ranks compounds. Both use the same tier vocabulary and both refresh on a quarterly editorial cadence.